RVP

Drug Catalog - Product Detail

BUPROPION HCL ER (SR) TB 150MG 60

NDC Mfr Size Str Form
47335-0737-86 SUN PHARMACEUTICALS 60 150MG TABLET
Product Image

PACKAGE FILES

Package Image
Package Image
Generic Name
Substance Name
Product Type
Route
Application Number
Description
DESCRIPTION SECTION Bupropion hydrochlorideextended-release tablet, USP (SR), an antidepressant of the aminoketone class, is chemically unrelated to tricyclic, tetracyclic, selective serotonin re-uptake inhibitor, or other known antidepressant agents. Its structure closely resembles that of diethylpropion; it is related to phenylethylamines. It is designated as (±)-1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]-1-propanone hydrochloride. The molecular weight is 276.2. The molecular formula is C13H18ClNO•HCl. Bupropion hydrochloride powder is white, crystalline, and highly soluble in water. It has a bitter taste and produces the sensation of local anesthesia on the oral mucosa. The structural formula is: Bupropion hydrochlorideextended-release tablets, USP (SR) are supplied for oral administration as 100 mg, 150 mg and 200 mg white to off white, film-coated, sustained-release tablets. Each tablet contains the labeled amount of bupropion hydrochloride, USP and the inactive ingredients: hydroxypropyl cellulose, saccharin, anhydrous lactose, colloidal silicon dioxide, talc, stearic acid, polyvinyl alcohol, titanium dioxide and polyethylene glycol 3350. For 100 mg strength - It meets USP dissolution test 7. For 150 mg and 200 mg strengths - It meets USP dissolution test 2. image description
How Supplied
HOW SUPPLIED SECTION Bupropion hydrochloride extended-release tablets, USP (SR), 100 mg of bupropion hydrochloride, are white to off white colored, round shaped, bevel edged biconvex film-coated tablets debossed with “736” on one side and plain on the other side. Bottles of 60’s with Child Resistant Cap . . . . . . . . . . . . . . . . . . . . . . . . . . NDC 47335-736-86 Bottles of 100’s with Child Resistant Cap . . . . . . . . . . . . . . . . . . . . . . . . . NDC 47335-736-88 Bottles of 100’s with Non Child Resistant Cap . . . . . . . . . . . . . . . . . . . . . NDC 47335-736-08 Bottles of 500’s with Non Child Resistant Cap . . . . . . . . . . . . . . . . . . . . . NDC 47335-736-13 Bupropion hydrochloride extended-release tablets, USP (SR), 150 mg of bupropion hydrochloride, are white to off white colored, round shaped, bevel edged biconvex film-coated tablets debossed with “737” on one side and plain on the other side. Bottles of 60’s with Child Resistant Cap . . . . . . . . . . . . . . . . . . . . . . . . . . NDC 47335-737-86 Bottles of 100’s with Child Resistant Cap . . . . . . . . . . . . . . . . . . . . . . . . . NDC 47335-737-88 Bottles of 100’s with Non Child Resistant Cap . . . . . . . . . . . . . . . . . . . . . NDC 47335-737-08 Bottles of 500’s with Non Child Resistant Cap . . . . . . . . . . . . . . . . . . . . . NDC 47335-737-13 Bupropion hydrochloride extended-release tablets, USP (SR), 200 mg of bupropion hydrochloride, are white to off white colored, round shaped, bevel edged biconvex film-coated tablets debossed with “738” on one side and plain on the other side. Bottles of 60’s with Child Resistant Cap . . . . . . . . . . . . . . . . . . . . . . . . . . NDC 47335-738-86 Bottles of 100’s with Child Resistant Cap . . . . . . . . . . . . . . . . . . . . . . . . . NDC 47335-738-88 Bottles of 100’s with Non Child Resistant Cap . . . . . . . . . . . . . . . . . . . . . NDC 47335-738-08 Bottles of 500’s with Non Child Resistant Cap . . . . . . . . . . . . . . . . . . . . . NDC 47335-738-13 Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° and 30°C (59° and 86°F) [see USP Controlled Room Temperature]. Dispense in a tight, light-resistant container as defined in the USP.
Indications & Usage
INDICATIONS & USAGE SECTION Bupropion hydrochloride extended-release tablets, USP (SR)are indicated for the treatment of major depressive disorder (MDD), as defined by the Diagnostic and Statistical Manual (DSM). The efficacy of bupropion in the treatment of a major depressive episode was established in two 4-week controlled inpatient trials and one 6-week controlled outpatient trial of adult subjects with MDD [see Clinical Studies ( 14 )]. The efficacy of bupropion hydrochloride extended-release tablets, USP (SR) in maintaining an antidepressant response for up to 44 weeks following 8 weeks of acute treatment was demonstrated in a placebo-controlled trial [see Clinical Studies ( 14 )].
Dosage and Administration
DOSAGE & ADMINISTRATION SECTION 2.1 General Instructions for Use To minimize the risk of seizure, increase the dose gradually [see Warnings and Precautions ( 5.3 )]. Bupropion hydrochloride extended-release tablets (SR) should be swallowed whole and not crushed, divided, or chewed. Bupropion hydrochloride extended-release tablets (SR) may be taken with or without food. The usual adult target dose for bupropion hydrochloride extended-release tablets (SR) is 300 mg per day, given as 150 mg twice daily. Initiate dosing with 150 mg per day given as a single daily dose in the morning. After 3 days of dosing, the dose may be increased to the 300 mg per day target dose, given as 150 mg twice daily. There should be an interval of at least 8 hours between successive doses. A maximum of 400 mg per day, given as 200 mg twice daily, may be considered for patients in whom no clinical improvement is noted after several weeks of treatment at 300 mg per day. To avoid high peak concentrations of bupropion and/or its metabolites, do not exceed 200 mg in any single dose. It is generally agreed that acute episodes of depression require several months or longer of antidepressant drug treatment beyond the response in the acute episode. It is unknown whether the dose of bupropion hydrochloride extended-release tablets (SR) needed for maintenance treatment is identical to the dose that provided an initial response. Periodically reassess the need for maintenance treatment and the appropriate dose for such treatment. 2.2 Dose Adjustment in Patients With Hepatic Impairment In patients with moderate to severe hepatic impairment (Child-Pugh score: 7 to 15), the maximum dose of bupropion hydrochloride extended-release tablets (SR) is 100 mg per day or 150 mg every other day. In patients with mild hepatic impairment (Child-Pugh score: 5 to 6), consider reducing the dose and/or frequency of dosing [see Use in Specific Populations ( 8.7 ), Clinical Pharmacology ( 12.3 )]. 2.3 Dose Adjustment in Patients With Renal Impairment Consider reducing the dose and/or frequency of bupropion hydrochloride extended-release tablets (SR) in patients with renal impairment (Glomerular Filtration Rate <90 mL/min) [see Use in Specific Populations ( 8.6 ), Clinical Pharmacology ( 12.3 )]. 2.4 Switching a Patient To or From a Monoamine Oxidase Inhibitor (MAOI) Antidepressant At least 14 days should elapse between discontinuation of an MAOI intended to treat depression and initiation of therapy with bupropion hydrochloride extended-release tablets (SR). Conversely, at least 14 days should be allowed after stopping bupropion hydrochloride extended-release tablets (SR) before starting an MAOI antidepressant [see Contraindications ( 4 ), Drug Interactions ( 7.6 )]. 2.5 Use of Bupropion Hydrochloride Extended-Release Tablets (SR) With Reversible MAOIs Such as Linezolid or Methylene Blue Do not start bupropion hydrochloride extended-release tablets (SR) in a patient who is being treated with a reversible MAOI such as linezolid or intravenous methylene blue. Drug interactions can increase the risk of hypertensive reactions. In a patient who requires more urgent treatment of a psychiatric condition, non-pharmacological interventions, including hospitalization, should be considered [see Contraindications ( 4 ), Drug Interactions ( 7.6 )]. In some cases, a patient already receiving therapy with bupropion hydrochloride extended-release tablets (SR) may require urgent treatment with linezolid or intravenous methylene blue. If acceptable alternatives to linezolid or intravenous methylene blue treatment are not available and the potential benefits of linezolid or intravenous methylene blue treatment are judged to outweigh the risks of hypertensive reactions in a particular patient, bupropion hydrochloride extended-release tablets (SR) should be stopped promptly, and linezolid or intravenous methylene blue can be administered. The patient should be monitored for 2 weeks or until 24 hours after the last dose of linezolid or intravenous methylene blue, whichever comes first. Therapy with bupropion hydrochloride extended-release tablets (SR) may be resumed 24 hours after the last dose of linezolid or intravenous methylene blue. The risk of administering methylene blue by non-intravenous routes (such as oral tablets or by local injection) or in intravenous doses much lower than 1 mg/kg with bupropion hydrochloride extended-release tablets (SR) is unclear. The clinician should, nevertheless, be aware of the possibility of a drug interaction with such use [see Contraindications ( 4 ), Drug Interactions ( 7.6 )].